In an interview with Reuters, the head of the sovereign wealth fund of the Russian Direct Investment Fund (RDIF) said that Russian hospitals can provide this drug to patients from June 1 1, which is enough to treat about 60,000 people every month.
At present, there is no approved vaccine for COVID-19 in the world, and the global scientific community has not yet reached a consensus on the efficacy of Russian improved antiviral drugs.
On May 3rd, Kloc-0, the first Russian drug "Avifavir" used to fight COVID-19 in Russia was approved by the Russian Ministry of Health. On the same day, Russian Health Minister Murashko announced that the vaccine developed by Russia will start clinical trials in about two weeks.
Kirill Dmitriev, head of the Russian direct investment foundation, said that the clinical trial involved 330 people and showed that the drug could successfully treat the virus within four days in most cases.
He said that the clinical trial plan will end in a week or so, and more clinical trials will be conducted. He added that the Ministry of Health has approved the use of this drug in the special acceleration process and started production in March.